- Home
- SLGB vs MIRA Comparison
SLGB vs MIRA Comparison
Compare SLGB & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | MIRA |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3M | 53.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SLGB | MIRA |
|---|---|---|
| Price | $1.16 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 108.3K | ★ 133.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $0.81 |
| 52 Week High | $6.02 | $2.45 |
Technical Indicators
Market Signals| Indicator | SLGB | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 38.12 |
| Support Level | $0.97 | $1.14 |
| Resistance Level | $1.48 | $1.38 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 7.33 | 29.17 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.